Cost-minimization analysis of treatment of gastroesophageal reflux disease: Implications of varying holding time on conclusions

European Journal of Pharmaceutical Sciences

Volumn 21, Issue 2-3, 2004, Pages 171-178

  Kivioja, Akseli ^a   Linnosmaa, Ismo ^a   Vehviläinen, Arto ^a   Vohlonen, Ilkka ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Cost minimization analysis; Economic analysis; Gastroesophageal reflux disease

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DOSE RESPONSE; DRUG COST; EXPERT SYSTEM; FINLAND; GASTROESOPHAGEAL REFLUX; HUMAN; MEDLINE; OUTCOMES RESEARCH; PHYSICIAN; PRIORITY JOURNAL; PROBABILITY; STOMACH PH;

EID: 0742321965     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2003.10.004     Document Type: Article

References (29)

1. Bell N., Burget D., Howden C., Wilkinson J., Hunt R. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 51:1992;59-67.
2. Bell N., Hunt R. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut. 33:1992;118-124.
3. Blum R., Shi H., Karol M., Greski-Rose P., Hunt R. The comparative effects of lansoprazole with omeprazole and ranitidine in suppressing gastric acid secretion. Clin. Ther. 19:1997;1013-1023.
4. Castell D., DeVault K. Guidelines for the diagnosis and therapeutic approach to gastroesophageal reflux disease. Arch. Intern. Med. 155:1995;2165-2173.
5. Chiba N., De Gara C., Wilkinson J., Hunt R. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 112:1997;1798-1810.
6. Data Professional, 2001. TreeAge Software, Williamstown.
7. Dent J., Brun A., Fendrick A., Fennerty M., Janssens J., Kahrilas P., Lauritsen K., Reynolds J., Shaw M., Talley N. An evidence-based appraisal of reflux disease management - the Genval workshop report. Gut. 44:1999;S1-S16.
8. DeVault K. Overview of medical therapy for gastroesophageal reflux disease. Gastroenterol. Clin. North Am. 28:1999;831-845.
9. Drummond, M., O'Brien, B., Stoddart, G., Torrance, G., 1997. Cost-effectiveness analysis. In: Drummond, M., O'Brien, B., Stoddart, G., Torrance, G. (Eds.), Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, New York, pp. 97-138.
10. Florent C., Forestier S. Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30. mg and pantoprazole 40 mg Eur. J. Gastroenterol. Hepatol. 9:1997;195-200.
11. Geus W., Mulder P., Nicolai J., Van Den Boomgaard D., Lamers C. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects. Aliment Pharmacol. Ther. 12:1998;329-335.
12. Howden C., Burget D., Hunt R. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease. Scand. J. Gastroenterol. 29:1994;79-82.
13. Hunt R. Importance of pH control in the management of GERD. Arch. Intern. Med. 159:1999;649-657.
14. Isolauri J., Laippala P. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann. Med. 27:1995;67-70.
15. Katz P., Xue S., Castell D. Control of intragastric pH with omeprazole 20. mg, omeprazole 40 mg and lansoprazole 30 mg Aliment Pharmacol. Ther. 15:2001;647-652.
16. Klinkenberg-Knol E., Jansen J., Festen H., Meuwissen S., Lamers C. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet. 1:1987;345-351.
17. Kuo B., Castell D. Optimal dosing of omeprazole 40. mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls Am. J. Gastroenterol. 91:1996;1532-1538.
18. Lind T., Rydberg L., Kylebäck A., Jonsson A., Andersson T., Hasselgren G., Holmberg J., Röhss K. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol. Ther. 14:2000;861-867.
19. Lundell L., Dent J., Bennett J., Blum A., Armstrong D., Galmiche J., Johnsson F., Hongo M., Richter J., Spechler S., Tytgat G., Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 45:1999;172-180.
20. Petitti, D., 2000. Decision analysis. In: Petitti, D. (Ed.), Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis, Methods for Quantitative Synthesis in Medicine. Oxford University press, New York, pp. 17-28.
21. Pharmaca Fennica 2001, 2000. West Point Ltd., Rauma (in Finnish).
22. Pikkarainen P. Reflux oesophagitis. Duodecim. 116:2000;1885-1891. in Finnish.
23. Pikkarainen P., Isolauri J. Medical treatment of gastro-oesophageal reflux disease. Duodecim. 110:1994;1845-1851. in Finnish.
24. Stedman C., Barclay M. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol. Ther. 14:2000;963-978.
25. Tefera S., Hatlebakk J., Berstad A. Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease. Am. J. Gastroenterol. 96:2001;969-974.
26. Vantrappen G., Rutgeerts L., Schurmans P., Coenegrachts J.-L. Omeprazole (40. mg) is superior to ranitidine in the short-term treatment of ulcerative reflux esophagitis Dig. Dis. Sci. 33:1988;523-529.
27. Wienbeck M., Barnert J. Epidemiology of reflux disease and reflux esophagitis. Scand. J. Gastroenterol. Suppl. 156:1989;7-13.
28. Williams M., Blanshard C., Millson C., Sercombe J., Pounder R. A placebo-controlled study to assess the effects or 7-day dosing with 10, 20 and 40. mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects Aliment Pharmacol. Ther. 14:2000;691-699.
29. Williams M., Sercombe J., Hamilton M., Pounder R. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol. Ther. 12:1998;1079-1089.